Tirzepatide, a recently approved medication, is creating significant interest in the scientific community as a potential treatment for both diabetes, type 2 and reducing body fat. This dual-action drug works by targeting two separate receptors, GLP-1 and GIP, leading to enhanced glucose control and notable slimming in testing. While initial data ar